212 related articles for article (PubMed ID: 38062450)
21. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
Zhao W; Liang Z; Yao Y; Ge Y; An G; Duan L; Yao J
Cancer Immunol Immunother; 2024 May; 73(7):131. PubMed ID: 38748299
[TBL] [Abstract][Full Text] [Related]
22. Bioinformatics-based analysis of programmed cell death pathway and key prognostic genes in gastric cancer: Implications for the development of therapeutics.
Huang L; Xiong W; Cheng L; Li H
J Gene Med; 2024 Jan; 26(1):e3590. PubMed ID: 37670467
[TBL] [Abstract][Full Text] [Related]
23. A new risk model based on a 11-m
Lei L; Li N; Yuan P; Liu D
BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
[TBL] [Abstract][Full Text] [Related]
24. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
[TBL] [Abstract][Full Text] [Related]
25. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
26. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
Zhang S; Lv M; Cheng Y; Wang S; Li C; Qu X
BMC Cancer; 2021 Dec; 21(1):1324. PubMed ID: 34893046
[TBL] [Abstract][Full Text] [Related]
27. Correlation analysis of lipid metabolism genes with the immune microenvironment in gastric cancer and the construction of a novel gene signature.
Li Y; Chen X; Zhang R; Chen M; Shen J; Wu J; Yu J; Sun Q
Clin Transl Oncol; 2023 May; 25(5):1315-1331. PubMed ID: 36520384
[TBL] [Abstract][Full Text] [Related]
28. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy.
Yuan Q; Deng D; Pan C; Ren J; Wei T; Wu Z; Zhang B; Li S; Yin P; Shang D
Front Immunol; 2022; 13():951137. PubMed ID: 35990657
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.
Wang JB; Gao YX; Ye YH; Zheng QL; Luo HY; Wang SH; Zhang T; Jin QW; Zheng CH; Li P; Lin JX; Chen QY; Cao LL; Yang YH; Huang CM; Xie JW
Theranostics; 2024; 14(7):2915-2933. PubMed ID: 38773976
[No Abstract] [Full Text] [Related]
30. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer.
Liu Z; Sun L; Peng X; Zhu J; Wu C; Zhu W; Huang C; Zhu Z
Apoptosis; 2024 Jun; 29(5-6):799-815. PubMed ID: 38347337
[TBL] [Abstract][Full Text] [Related]
31. Systematic Analysis of Tumor Stem Cell-related Gene Characteristics to Predict the PD-L1 Immunotherapy and Prognosis of Gastric Cancer.
Wang C; Chen Y; Zhou R; Yang Y; Fang Y
Curr Med Chem; 2024; 31(17):2467-2482. PubMed ID: 37936456
[TBL] [Abstract][Full Text] [Related]
32. Development and verification of an immune-related gene prognostic index for gastric cancer.
Zhang C; Liu T; Wang J; Zhang J
Sci Rep; 2022 Sep; 12(1):15693. PubMed ID: 36127384
[TBL] [Abstract][Full Text] [Related]
33. Integrated single-cell RNA sequencing analysis reveals a mesenchymal stem cell-associated signature for estimating prognosis and drug sensitivity in gastric cancer.
Shen K; Chen B; Gao W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11829-11847. PubMed ID: 37410142
[TBL] [Abstract][Full Text] [Related]
34. Expression of ferroptosis-related gene correlates with immune microenvironment and predicts prognosis in gastric cancer.
Song S; Shu P
Sci Rep; 2022 May; 12(1):8785. PubMed ID: 35610340
[TBL] [Abstract][Full Text] [Related]
35. A novel necroptosis-related gene index for predicting prognosis and a cold tumor immune microenvironment in stomach adenocarcinoma.
Khan M; Lin J; Wang B; Chen C; Huang Z; Tian Y; Yuan Y; Bu J
Front Immunol; 2022; 13():968165. PubMed ID: 36389725
[TBL] [Abstract][Full Text] [Related]
36. Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment.
Li X; Wang Y; Zhai Z; Mao Q; Chen D; Xiao L; Xu S; Wu Q; Chen K; Hou Q; He Q; Shen Y; Yang M; Peng Z; He S; Zhou X; Tan H; Luo S; Fang C; Li G; Chen T
J Exp Clin Cancer Res; 2023 Aug; 42(1):206. PubMed ID: 37563649
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a novel lipid metabolism-related gene signature to predict outcomes and the tumor immune microenvironment in gastric cancer by integrated analysis of single-cell and bulk RNA sequencing.
Zhang J; Wang H; Tian Y; Li T; Zhang W; Ma L; Chen X; Wei Y
Lipids Health Dis; 2023 Dec; 22(1):212. PubMed ID: 38042786
[TBL] [Abstract][Full Text] [Related]
38. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
Front Immunol; 2022; 13():992060. PubMed ID: 36311733
[TBL] [Abstract][Full Text] [Related]
39. Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer.
Qiu F; Zhu Y; Shi Y; Ji J; Jin Y
Dis Markers; 2021; 2021():4251763. PubMed ID: 34804261
[TBL] [Abstract][Full Text] [Related]
40. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
